The Strategic Timing of Antiretroviral Treatment (START) trial randomized persons with CD4+ >500 cells/µL to immediate or deferred antiretroviral treatment (ART). START demonstrated that early ART for HIV is more beneficial than waiting until CD4+ count drops below 350 cells/µL. We examined whether CD4+ count response differed between those recently infected and those infected for a longer duration.
START participants were classified into groups by duration of HIV infection (self-report)/diagnosis (documented) at study entry: 1) recently infected (<6 months) by self-report or recently infected using a multi-assay algorithm (MAA) based on serologic markers of early infection (group 1; n=373); 2) diagnosis date <6 months but recent infection not confirmed by MAA or diagnosis date 6-24 months (group 2; n=2,635); or 3) diagnosis date ≥2 years (group 3; n=1,605). Longitudinal regression was used to compare CD4+ count levels during follow-up for the immediate and deferred ART arms by duration of infection. In the deferred arm, time to CD4+ <350 cells/µL or AIDS (threshold for initiating ART) was compared by duration of infection, with and without censoring for ART initiation.
At entry, individuals recently infected (group 1) were younger than those in groups 2 and 3 (31 vs 34 vs 40 (years), p<0.001); and more likely to be MSM (75% vs 59% vs 44%, p<0.001). Those recently infected had a higher median baseline viral load than the other two groups (27199 vs 13550 vs 9744 (copies/mL), p<0.001). The mean CD4+ difference (immediate minus deferred) over follow-up was significantly greater for those in the recent infection group compared to the two other groups (230 vs 202 and 171 cells/µL; p<0.001). Time to CD4+ decline to 350 cells/µL or AIDS was faster among those recently infected compared to those who were not (Figure). Rates for the three groups with ART censoring were 19.7, 16.0, and 11.7 per 100 person-years (p<0.001).
Our results demonstrate that the CD4+ count difference over follow up between the immediate and deferred ART arms was greater among those recently infected. Immediate treatment after HIV infection likely has a greater impact than previously thought, as selection into the START trial required individuals to have two CD4s > 500 cell/µL and those enrolled were less likely to be recently infected and more likely to be individuals with decreased pathogenic progression as measured by CD4+ decline.